Navigation Links
Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
Date:2/8/2013

SAN DIEGO, February 8, 2013 /PRNewswire/ --

Shire plc (LSE: SHP, NASDAQ: SHPG), today announced the initiation of a Phase 3 study designed to evaluate the efficacy and safety of ABH001, its dermal substitute therapy, for the treatment of non-healing wounds in patients with Epidermolysis Bullosa (EB), a group of rare genetic skin disorders that begin to manifest at birth or early childhood and occur in approximately 19 per 1 million live births in the US. [i]  

"People affected by EB suffer skin blisters and almost constant, acute pain and scarring," said the study's Principal Investigator, H. Alan Arbuckle , MD, Section Head Pediatric Dermatology Kaiser Permanente Colorado, Wound Care Consultant, Epidermolysis Bullosa Center of Excellence, The Children's Hospital, Aurora Colorado . "The current standard of care is daily wound care, bandaging and pain management. I am excited to be involved in testing the efficacy and safety of ABH001 as a potential treatment option for these patients."  

ABH001 for EB has been granted an orphan drug designation in the US and EU, and has also received Fast Track designation from the US Food and Drug Administration (FDA), which is aimed at facilitating the development and expediting the review of drugs and biologics that fill an unmet medical need. In addition, the European Medicines Agency's Pediatric Committee has agreed on a pediatric investigation plan for ABH001 for the treatment of EB.

The new Phase 3 study is a multi-site, prospective, randomized, open-label, intra-subject controlled trial evaluating the efficacy and safety of ABH001 to initiate healing and reduce the wound surface area of selected stalled, chronic cutaneous wounds associated with generalized EB. Approximately 20 subjects with generalized EB age
'/>"/>

SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
2. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
3. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
4. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
5. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
6. Shire Changes its NASDAQ Ticker Symbol to SHPG
7. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
8. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
9. Shire Reaches Agreement in Principle With U.S. Government
10. Palm Beach Residents to Learn How the Future of Regenerative Medicine Will Combat Aging
11. ODT Forum Presents Regenerative Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... $2.1 million. The orders consist of three large odour control ... . "These orders are consistent with the ... Peter Bruijns , President and CEO. "After a difficult ... we are now beginning to see sales growth. Our lower ...
(Date:9/2/2014)... September 02, 2014 PMG Research, ... 11th clinical research site: PMG Research of Rocky Mount. ... operation of the clinical research department at Boice-Willis ... presence in eastern North Carolina. This new site enhances ... patients in Rocky Mount and the surrounding communities, this ...
(Date:9/2/2014)... Md. , Sept. 2, 2014  Spherix Incorporated ... and monetization of intellectual property, today announced that the ... patents to the Company in the month of August ... patents.  The issued patents are: ... , U.S.RE45,081 issued August 19, 2014; and , ...
(Date:9/2/2014)... September 2, 2014 Culot brings ... and lab management services  BioData, producer of ... pleased to announce the appointment of Louis Culot ... served as VP Marketing and Business Development at BioDiscovery ... and clinical applications. Previously, Culot worked for ...
Breaking Biology Technology:PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 3United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 2Louis Culot Appointed as BioData's CEO 2
... empower transplant patients ... and their ... (Pink Sheets: ALPMF), a leader in the field of transplantation, ... announced a collaborative partnership to jointly,develop further materials for the ...
... new class of anti-infectives, to ... advise Company on pexiganan development, WELLESLEY HILLS, Mass., Oct. ... following its,acquisition of rights to pexiganan, Michael Zasloff, M.D. has ... skin of the African clawed frog while at NIH (National ...
... SUNNYVALE, Calif., Oct. 16 Kyphon Inc.,(Nasdaq: KYPH ... the merger agreement with Medtronic, Inc. (NYSE: MDT ... As previously announced, on July 26, 2007, Kyphon entered ... Medtronic,agreed to acquire all of the outstanding shares of ...
Cached Biology Technology:Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program 2Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program 3MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Company's Scientific Advisory Board 2MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Company's Scientific Advisory Board 3MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Company's Scientific Advisory Board 4MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Company's Scientific Advisory Board 5Kyphon Stockholders Approve Merger with Medtronic 2
(Date:9/2/2014)... With their long, spiky legs and their propensity for ... stuff of nightmares. And now research from North Carolina ... spread into homes across the eastern United States. , ... or pose any kind of threat to humans," says ... State and lead author of a paper about the ...
(Date:9/2/2014)... of lithographic limestone is well known as a ... that area (for example, Archaeopteryx). Now, for the ... the French equivalent of these outcrops - discoveries ... known water treader. , Despite the abundance of ... have been obtained from the Late Kimmeridgian equivalents ...
(Date:9/2/2014)... a hot oven, you rapidly pull your hand away. ... sensing and responding to such painful stimuli, they are ... have made a surprising discovery about the role of ... have built a structural model of the molecule. These ... may help direct new strategies to treat pain in ...
Breaking Biology News(10 mins):Researchers find Asian camel crickets now common in US homes 2Exceptionally well preserved insect fossils from the Rhône Valley 2Surprising new role for calcium in sensing pain 2Surprising new role for calcium in sensing pain 3
... occurring in the Sundarbans, resulting in as much as 200m ... published today (11th Jan) in Remote Sensing by ... as human development thrives, and global temperature continues to rise, ... at alarming rates. This will inevitably lead to species loss ...
... are "apple-shaped" with fat more concentrated around the abdomen ... such as heart disease and diabetes than those who are ... thighs. But new research conducted at UC Davis ... and Metabolism provides further evidence that the protective benefits ...
... Oxidative stress is a primary villain in a host ... to Alzheimer,s disease, Amyotrophic Lateral Sclerosis and Parkinson,s disease. ... Research Institute (TSRI) have found that blocking the interaction ... neurons associated with these neurodegenerative diseases, suggesting a potential ...
Cached Biology News:Bengali forests are fading away 2UC Davis study deflates notion that pear-shaped bodies more healthy than apples 2UC Davis study deflates notion that pear-shaped bodies more healthy than apples 3Scripps Florida scientists uncover potential drug target to block cell death in Parkinson's disease 2
Form: Ready to use Applications: ELISA...
EnzChek Ultra Xylanase Assay Kit *500 assays*...
Goat polyclonal to p27 KIP 1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-KRPATDDS STQNK, corresponding to Internal sequence amino acids 153-165 of Human p27 KIP 1 ...
Defender against cell death 1...
Biology Products: